ribavirin has been researched along with HPV Infection in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Burman, B; Drutman, SB; Fury, MG; Ho, AL; Katabi, N; Pfister, DG; Wong, RJ | 1 |
| Dunn, LA; Fury, MG; Haque, SS; Ho, AA; Katabi, N; Pfister, DG; Sherman, EJ | 1 |
| Hamrock, DJ; Shrestha, NK | 1 |
| Aoki, FH; Gonçalves, FL; Pavan, MH; Velho, PE; Vigani, AG | 1 |
1 trial(s) available for ribavirin and HPV Infection
| Article | Year |
|---|---|
Phase I study of induction chemotherapy with afatinib, ribavirin, and weekly carboplatin and paclitaxel for stage IVA/IVB human papillomavirus-associated oropharyngeal squamous cell cancer.
Topics: Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Carboplatin; Carcinoma, Squamous Cell; Dose-Response Relationship, Drug; Humans; Induction Chemotherapy; Male; Middle Aged; Neoplasm Staging; Oropharyngeal Neoplasms; Paclitaxel; Papillomaviridae; Papillomavirus Infections; Progression-Free Survival; Ribavirin | 2018 |
3 other study(ies) available for ribavirin and HPV Infection
| Article | Year |
|---|---|
Pharmacodynamic and therapeutic pilot studies of single-agent ribavirin in patients with human papillomavirus-related malignancies.
Topics: Alphapapillomavirus; Cell Line, Tumor; Eukaryotic Initiation Factor-4E; Humans; Papillomaviridae; Papillomavirus Infections; Pilot Projects; Ribavirin | 2022 |
Successful treatment of disseminated human papillomavirus infection with pegylated interferon and ribavirin.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antiviral Agents; Drug Therapy, Combination; Humans; Interferons; Male; Papillomavirus Infections; Psoriasis; Ribavirin; Treatment Outcome | 2010 |
Treatment of human papillomavirus with peg-interferon alfa-2b and ribavirin.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Papillomavirus Infections; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2007 |